Drug
Deferoxamine (DFO)
Deferoxamine (DFO) is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 66.7%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
66.7%
Based on 2 completed trials
Completion Rate
67%(2/3)
Active Trials
1(25%)
Results Posted
100%(2 trials)
Terminated
1(25%)
Phase Distribution
Ph phase_2
2
50%
Ph phase_1
1
25%
Ph not_applicable
1
25%
Phase Distribution
1
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
2(50.0%)
N/ANon-phased studies
1(25.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
66.7%
2 of 3 finished
Non-Completion Rate
33.3%
1 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(2)
Terminated(1)
Detailed Status
Completed2
Terminated1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
66.7%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (25.0%)
Phase 22 (50.0%)
N/A1 (25.0%)
Trials by Status
terminated125%
completed250%
recruiting125%
Recent Activity
1 active trials
Showing 4 of 4
recruitingphase_1
A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis
NCT05184816
completednot_applicable
Comparison of Deferasirox and Desferoxamine in Patients of β-Thalassemia Major With Iron Overload
NCT06468423
terminatedphase_2
Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron Overload
NCT01459718
completedphase_2
Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients
NCT00110617
Clinical Trials (4)
Showing 4 of 4 trials
NCT05184816Phase 1
A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis
NCT06468423Not Applicable
Comparison of Deferasirox and Desferoxamine in Patients of β-Thalassemia Major With Iron Overload
NCT01459718Phase 2
Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron Overload
NCT00110617Phase 2
Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4